CytomX Therapeutics, Inc. — Director's Dealing 2021

Oct 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CytomX Therapeutics, Inc. (CTMX)
CIK: 0001501989
Period of Report: 2021-10-24

Reporting Person: HANNAH ALISON L. (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-24	Stock Option (Right to Buy)	$5.34	A	40000	Acquired	2031-10-23	Common Stock (40000)	Direct
2021-10-24	Performance Stock Units (PSUs)	$	A	30000	Acquired		Common Stock (30000)	Direct

Footnotes

F1: 1/48th of the shares subject to the option vest on each monthly anniversary measured from October 24, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

F2: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone within 1 year from grant date and 50% of the PSUs vest upon achievement of a certain performance-based milestone within 2 years from grant date.